Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 145,445 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: GBS Positive, Women in Labor Given Vancomycin for Prophylaxis
Interventions: Not listed
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Vaping, Nicotine Dependence
Interventions: Varenicline, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 25 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetic Foot Ulcer
Interventions: Placenta Stem Cells; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Underlying Liver Disease, Hepatitis, Fibrosis of Liver, Cirrhosis With Suspicion of Liver Cancer, Lesion on a Prior Ultrasound, CT or Outside MRI
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: FT-7051; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Scottsdale, Arizona • Aurora, Colorado • Chicago, Illinois + 5 more

Conditions: Leukemia
Interventions: loss of heterozygosity analysis, microarray analysis, polymorphism analysis, tumor replication error analysis; Genetic
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Overweight, Obesity
Interventions: LY4167586, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Schizophrenia
Interventions: LY500307 150mg, LY500307 75mg, Placebo, LY500307 25mg; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 4
States / cities: Indianapolis, Indiana

Conditions: Yellow Fever
Interventions: Not listed
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma, NSCLC Non-small Cell Lung Cancer, Squamous Cell Cancer of the Head and Neck, UC (Urothelial Cancer), MSI-H Cancer
Interventions: Decoy20, Tislelizumab; Drug
Lead sponsor: Indaptus Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 12
States / cities: Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 8 more

Conditions: Depression, Fatigue, Stage IIA Colorectal Cancer, Stage IIB Colorectal Cancer, Stage IIC Colorectal Cancer, Stage IIIA Colorectal Cancer, Stage IIIB Colorectal Cancer, Stage IIIC Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Appendix Cancer, Stomach Cancer, Gallbladder Cancer, Liver Cancer, Small Intestine Cancer, Large Intestine Cancer, Anal Cancer, Biliary Tract Cancer, Gastrointestinal Stromal Cancer
Interventions: Laboratory Biomarker Analysis, Questionnaire Administration, Daily Survey Administration, Yoga Skills Training, Attention Control, Actigraphy Assessment; Other · Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Winston-Salem, North Carolina • Nashville, Tennessee

Conditions: Laparotomy, Gynecologic Diseases
Interventions: Enhanced recovery protocol; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lung Cancer, Head and Neck Cancer
Interventions: Panobinostat (LBH589), erlotinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Natalizumab (Tysabri); Drug
Lead sponsor: Cornerstone Health Care, PA; Other
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Patchogue, New York • High Point, North Carolina • Portland, Oregon

Conditions: Metastatic Colorectal Cancer, Colon Cancer, Colorectal Cancer, Rectal Cancer
Interventions: Placebo, AMG 655, Modified FOLFOX6, Bevacizumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 61
States / cities: Hot Springs, Arkansas • Downey, California • La Jolla, California + 56 more

Conditions: Type2 Diabetes
Interventions: Abbott Freestyle Libre Pro, LifeStyle; Device · Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Fibromyalgia
Interventions: ASP0819, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 24
States / cities: Birmingham, Alabama • El Cajon, California • Sacramento, California + 21 more

Conditions: Schizophrenia
Interventions: Placebo, Emraclidine 10 mg, Emraclidine 30 mg; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 21
States / cities: Little Rock, Arkansas • Anaheim, California • Garden Grove, California + 18 more

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Blood Collection During Standard of Care Treatment; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Influenza, Human
Interventions: mIRV, bIRV AB, qIRV, QIV, bIRV AA, bIRV BB; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,158 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 100
States / cities: Athens, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more

Conditions: Diabetes, Hypoglycemia
Interventions: 13C-MRS procedure/Acetate infusion, Continuous glucose monitoring; Other · Device
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 40 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Baton Rouge, Louisiana • New Orleans, Louisiana

Conditions: Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions: [14C]CCX168; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Breast Cancer, DCIS
Interventions: LifeExtend-AI; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Subdural Hematoma
Interventions: Tranexamic Acid; Drug
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Phoenix, Arizona

Search by objective public record fields.

Intrapartum Vancomycin for Group B Streptococcus (GBS) Prophylaxis

Varenicline For Nicotine Vaping Cessation In Non Smoker Vaper Adolescents

Placental Cells for Diabetic Foot Ulcers

Rapid 10-Minute Liver MRI Protocol in Patients With Suspected Hepatocellular Carcinoma

A Study of FT-7051 in Men With MCRPC

Laboratory Study of Lymphoblasts in Young Patients With High-Risk Acute Lymphoblastic Leukemia

A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia

Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

Programs To Support You During Chemotherapy

Enhanced Recovery After Surgery: A RCT of Perioperative Management of Gynecologic Patients

Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers

NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness

Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer

Validation of Machine Learning Based Personalized Nutrition Algorithm to Reduce Postprandial Glycemic Excursions Among North American Individuals With Newly Diagnosed Type 2 Diabetes

A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia

A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza

Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Complications in Diabetic Patients

A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants

Pilot Study of a an App to Improve Medication Adherence in Breast Cancer Survivors Receiving AIs

A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population